image

Investors

Corporate Profile

Nurix Therapeutics is a biopharmaceutical company focused on the discovery, development, and commercialization of small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and other challenging diseases. Leveraging Nurix’s extensive expertise in E3 ligases together with its proprietary DNA-encoded libraries, Nurix has built DELigase, an integrated discovery platform to identify and advance novel drug candidates that can modulate proteins within the cell.

Primary IR Contact

Elizabeth Wolffe, Ph.D.
Wheelhouse Life Science Advisors
wolffe@wheelhouselsa.com
 

 

Contact IR FormTo request information, please fill out and submit the form below: